June 05-08, 2024
Milan, Italy

European Association for the Study of Liver Disease .

Explore more information for Gilead Liver Diseases therapies
Results (16)

Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver

Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): Interim results for 2 years from the ASSURE study

Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy.

Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy

The burden of chronic hepatitis delta in Italy: potential impacts and effects of bulevirtide through cost of illness and cost consequence analysis

Differential expression and sequence variants of sodium taurocholate cotransporting polypeptide (NTCP) do not affect HDV inhibition by Bulevirtide (BLV)

Intrahepatic sodium taurocholate co-transporting polypeptide gene transcript and membrane-localized protein expression changes in chronic hepatitis D patients following 48 weeks of treatment with Bulevirtide

No Amino Acid Substitution in HBV Pres1, HDAg, Or NTCP Associated With Suboptimal Response to Bulevirtide in Combination With Pegylated Interferon Alfa-2a Treatment in Participants With Chronic Hepatitis Delta: Results From MYR204, a Phase 2b Study

Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg monotherapy from the ongoing Phase 3 study, MYR301

48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2a in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204

Impact of bulevirtide given with or without nucleos(t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection

Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta

Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016-2022)

Description of age, sex, and characteristics of Hepatitis C patients in the SVR10K study: A real-world SOF/VEL analysis performed across five global regions

Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B

Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus